F-1: RedHill Biopharma Secures $25M Equity Line, Wins Lawsuit

RedHill Biopharma Ltd. filed an F-1 registration statement for the resale of up to 6.47 million American Depositary Shares by YA II PN, LTD., potentially raising up to $25 million, while also announcing a major legal victory and Nasdaq compliance.

Summary

• RedHill Biopharma Ltd. filed an F-1 registration statement for the resale of up to 6,465,559 American Depositary Shares (ADSs) by YA II PN, LTD. (YA), representing 64,655,590,000 ordinary shares.
• The offering includes up to 5,000,000 ADSs that RedHill may sell to YA under a Standby Equity Purchase Agreement for up to $25.0 million over 36 months, plus $1.0 million from an Initial Equity Issuance to YA.
• The Initial Equity Issuance to YA comprised 386,593 ADSs at $1.0235 per share and Pre-Funded Warrants for 590,446 ADSs at $1.0234 per warrant (exercise price $0.0001 per ADS).
• An additional 488,520 ADSs are issuable to YA as Commitment Shares for its irrevocable commitment, with 122,130 ADSs already issued and 366,390 ADSs to be issued in three equal installments on the 90th, 180th, and 270th day anniversaries of the Purchase Agreement.
• RedHill will not receive proceeds from YA's resale of these ADSs, but may receive up to $25.0 million from direct sales to YA under the Purchase Agreement, plus the $1.0 million from the Initial Equity Issuance.
• The purchase price for Advance Shares will be 95% of the Market Price on the trading day of the Advance Notice (Option 1) or 97% of the lowest daily VWAP over three consecutive trading days (Option 2).
• An Ownership Limitation prevents YA and its affiliates from beneficially owning more than 9.99% of outstanding ADSs.
• RedHill regained compliance with Nasdaq's Minimum Stockholders Equity Rule on December 1, 2025, after reporting a stockholders deficit of $4,683,000 as of December 31, 2024.
• The company won a summary judgment of approximately $8 million (including $6.5 million principal and $1.5 million accrued interest) against Kukbo Co. Ltd. on December 2, 2024, with an additional $1.82 million in legal costs awarded on August 11, 2025, bringing the total award to over $10.5 million.
• The main judgment against Kukbo became final and eligible for enforcement as of October 27, 2025, with 9% annual statutory interest continuing to accrue.
• RedHill entered into a joint commercialization agreement for Talicia in the U.S. with Cumberland Pharmaceuticals Inc., forming Talicia Holdings Inc. (70% RedHill, 30% Cumberland). Cumberland invested $4 million for its equity stake, payable in two tranches, and net revenues from U.S. sales of Talicia will be shared equally.
• An existing $10 million equity line of credit with Alumni Capital LP has generated approximately $3.3 million net proceeds from the sale of 2,247,136 ADSs at a weighted average price of $1.48 per ADS.
• An ATM program with H.C. Wainwright & Co., LLC has generated approximately $3.3 million net proceeds from the sale of 890,001 ADSs at a weighted average price of $3.85 per ADS.

Sentiment

Score: 6

Explanation: The filing presents a neutral to slightly positive outlook. While securing a new equity line and winning a significant legal judgment are positive for liquidity and stability, the potential for substantial dilution and the ongoing 'going concern' reference (from prior filings) temper overall enthusiasm. Regaining Nasdaq compliance is a positive, but the underlying financial health still requires significant capital.

Positives

• Regained compliance with Nasdaq's Minimum Stockholders Equity Rule on December 1, 2025, addressing a previous non-compliance issue.
• Secured a Standby Equity Purchase Agreement with YA II PN, LTD. for up to $25.0 million in potential gross proceeds, providing a flexible financing option for general corporate purposes.
• Received $1.0 million in gross proceeds from the Initial Equity Issuance to YA upon execution of the Purchase Agreement.
• Successfully won a summary judgment against Kukbo Co. Ltd., awarding over $10.5 million in total (including principal, accrued interest, and legal costs), with the main judgment final and eligible for enforcement as of October 27, 2025.
• Established a joint commercialization agreement for Talicia in the U.S. with Cumberland Pharmaceuticals Inc., including a $4 million investment from Cumberland for a 30% equity stake in Talicia Holdings Inc., which will share net revenues equally.
• Continued to generate capital through existing equity lines of credit with Alumni Capital LP (approximately $3.3 million to date) and an ATM program with H.C. Wainwright & Co., LLC (approximately $3.3 million to date).

Negatives

• Significant potential for dilution for existing shareholders due to the issuance and resale of up to 6,465,559 ADSs (representing approximately 55.94% of total outstanding ADSs) under the Purchase Agreement.
• The actual gross proceeds from the YA Purchase Agreement may be substantially less than $25 million, depending on market prices and limitations such as the 9.99% Ownership Limitation and Volume Thresholds.
• The Purchase Agreement includes a 75-day restriction on other variable rate transactions below the Initial Equity Purchase Price, potentially limiting access to alternative financing sources during this period.
• Reliance on third parties (Cumberland, Hyloris, Recipharm, Gaelan Medical, contract manufacturers) for key commercial operations, clinical trials, and manufacturing introduces operational and supply chain risks.
• Ceded significant control over Talicia's U.S. commercialization to a joint committee with Cumberland, which may lead to disagreements, deadlocks, or missed commercial opportunities.
• The company's financial statements included a 'going concern' reference, indicating substantial doubt about its ability to continue operations without additional financing.
• Previously faced Nasdaq delisting risks due to minimum bid price and market value of publicly held shares requirements, and there is no guarantee of long-term compliance.
• The award for legal fees in the Kukbo litigation (approximately $1.9 million) remains subject to an ongoing appeal until March 13, 2026, meaning full collection is not yet certain.
• Operations in Israel are subject to economic, political, geopolitical, and military conditions, including the ongoing conflict, which could disrupt business and supply chains.
• One member of management is currently subject to military service in the IDF, and further call-ups could lead to skilled labor shortages and impact business operations.
• Commercial insurance does not cover losses that may occur as a result of events associated with the security situation in the Middle East, and government coverage is not assured.

Risks

• Inability to obtain additional financing or successfully conclude a strategic business transaction, leading to a 'going concern' reference in financial statements.
• Failure to maintain compliance with Nasdaq listing standards, including minimum bid price and minimum stockholders' equity requirements, which could result in delisting.
• Substantial dilution to shareholders from sales and additional issuances of ADSs or other securities, potentially causing a decline in share price.
• The actual number of shares sold under the Purchase Agreement and the gross proceeds received are unpredictable due to fluctuating market prices and limitations (e.g., Ownership Limitation, Volume Threshold).
• Limitations under the Purchase Agreement, such as the 75-day restriction on other variable rate transactions, could limit the ability to obtain adequate financing on a timely basis or on acceptable terms.
• U.S. holders of ADSs may suffer adverse tax consequences if the company is characterized as a Passive Foreign Investment Company (PFIC).
• Ceding significant control over Talicia's U.S. commercialization to Cumberland, leading to dependence on Cumberland's performance and joint decision-making, which may result in disagreements, deadlocks, or missed commercial opportunities.
• Increased operational and supply chain risks due to divided responsibilities with Cumberland for Talicia's commercialization, potentially leading to inventory issues, distribution disruptions, or increased expenses.
• The minority sale of Talicia Holdings and joint control structure may limit the company's ability to unilaterally determine strategy, restructure, or pursue certain strategic transactions for Talicia.
• Potential for conflicts of interest and disputes regarding commercialization strategy, budgets, and contractual requirements within collaborative arrangements.
• Substantial costs and delays if the collaboration with Cumberland is terminated or otherwise fails, requiring the company to assume responsibilities or identify a replacement partner.
• Reliance on third parties for key commercial operations, clinical trials, manufacturing, and supply chain functions, with risks of non-performance, non-compliance, or financial difficulties.
• Exposure to significant drug product liability claims.
• Talicia or future commercial products may be withdrawn from the market by regulatory authorities.
• No assurance of successfully collecting all amounts awarded in the Kukbo lawsuit, and collection efforts may divert management attention and resources.
• Business and operations are directly affected by economic, political, geopolitical, and military conditions in Israel, including ongoing conflicts, potential for escalation, and disruptions to labor availability (e.g., military reserve duty call-ups).
• Commercial insurance does not cover losses that may occur as a result of events associated with the security situation in the Middle East, and government coverage is not assured.
• Risks from countries restricting business with Israel or boycotts of Israeli goods.
• Potential negative impact on the business environment in Israel due to proposed changes to the judicial system.

Future Outlook

The company aims to become a leading specialty biopharmaceutical company, primarily focused on GI, infectious diseases, medical countermeasures, and oncology, by advancing its clinical-stage therapeutic candidates like opaganib and RHB-107. Future commercialization of approved candidates is planned through licensing, other commercialization arrangements, or independent operations. The ability to raise the full $25 million from the YA Purchase Agreement depends on market conditions and meeting agreement conditions. The company intends to vigorously pursue collection of the Kukbo judgment and will reinvest any future earnings into business operations and expansion, with no plans for cash dividends in the foreseeable future.

Management Comments

• We intend to vigorously pursue the recovery of attorneys fees and the collection of the judgment.
• We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law.

Industry Context

Operating in the diverse and competitive specialty biopharmaceutical sector, the company's strategy of leveraging partnerships for commercialization, as seen with Cumberland Pharmaceuticals for Talicia, is a common approach for smaller biopharma firms to expand market reach and share costs/risks. The development pipeline targeting viral infections (COVID-19, Ebola) and pandemic preparedness reflects ongoing global health priorities. The use of equity lines of credit and ATM programs is a typical financing strategy for growth-stage biopharma companies, providing flexible capital access but often leading to dilution.

Corporate Governance

Legal Proceedings

• **Kukbo Co. Ltd. Litigation**: Filed lawsuit on September 2, 2022, due to Kukbo's default on a $5.0 million subscription agreement and a $1.5 million exclusive license agreement payment. Kukbo filed counterclaims for breach of contract, misrepresentation, and breach of good faith. On December 2, 2024, RedHill was awarded a summary judgment of approximately $8 million ($6.5 million principal + $1.5 million accrued interest), with Kukbo's counterclaims dismissed. On August 11, 2025, an additional $1.82 million in legal costs and expenses (including interest) was awarded. On September 23, 2025, the New York Supreme Court upheld the summary judgment on appeal. As of October 27, 2025, the main judgment (approximately $8.6 million including interest) became final and eligible for enforcement. The award for legal fees and expenses (approximately $1.9 million including interest) remains subject to an ongoing appeal until March 13, 2026. 9% annual statutory interest continues to accrue on both awards. RedHill won an attachment grant from Korea's Incheon District Court, seizing Kukbo's assets. A contingency fee agreement with Haynes and Boone, LLP (amended December 29, 2024) entitles the firm to a double-digit percentage of gross recovery, or standard hourly fees ($1.1 million as of December 31, 2024) if no collection within six months.

Related Party Transactions

• Standby Equity Purchase Agreement with YA II PN, LTD. for up to $25.0 million in ADSs, plus initial equity and commitment shares, providing a financing facility.
• Equity Line of Credit (Any Market Purchase Agreement) with Alumni Capital LP for up to $10 million in ADSs, serving as another financing facility.
• Joint commercialization agreement with Cumberland Pharmaceuticals Inc. for Talicia, where Cumberland invested $4 million for a 30% equity interest in Talicia Holdings Inc., establishing a strategic partnership.

Stakeholder Impact

• **Shareholders**: Face potential for significant dilution due to the issuance of new ADSs under the YA Purchase Agreement and other equity lines. The market price could experience volatility. However, the legal win and financing provide some stability.
• **Employees**: Potential impact from military reserve duty call-ups in Israel, which could lead to skilled labor shortages and operational challenges.
• **Customers**: Potential impact from operational or supply chain disruptions if collaborations fail or geopolitical events in Israel escalate, affecting product availability.
• **Creditors**: The 'going concern' reference in financial statements indicates potential risk, though the new financing agreements and the Kukbo judgment collection could improve the company's financial standing and ability to meet obligations.
• **Partners (YA, Alumni, Wainwright, Cumberland)**: Their interests are directly tied to the company's performance and the terms of their respective agreements, with YA and Alumni providing capital, Wainwright facilitating ATM sales, and Cumberland collaborating on commercialization.

Next Steps

• RedHill may elect to issue and sell up to 5,000,000 ADSs to YA under the Purchase Agreement from time to time over the next 36 months.
• YA will receive 366,390 ADSs as Subsequent Commitment Shares in three equal installments on the 90th, 180th, and 270th day anniversaries of the Purchase Agreement.
• The company intends to vigorously pursue the recovery of attorneys' fees and the collection of the judgment from Kukbo.
• The appeal for legal fees in the Kukbo litigation is ongoing until March 13, 2026.
• The company plans to advance its therapeutic candidates into clinical trials and complete development.
• The company will continue to explore strategic plans for other potential products and activities.
• The remaining $2 million tranche of Cumberland's investment in Talicia Holdings is due within 12 months of the October 17, 2025 agreement.

Key Dates

Recommendation

The company has secured a flexible financing mechanism and won a significant legal judgment, which are positive developments for liquidity and financial stability. Regaining Nasdaq compliance also removes an immediate threat. However, the potential for substantial dilution from the equity line, the ongoing 'going concern' reference (from prior filings, but still relevant context), and the inherent risks of a biopharmaceutical company (especially with a diverse pipeline and reliance on collaborations) suggest a 'Hold' recommendation. Investors should monitor the actual utilization of the equity line, the impact of dilution, and progress in collecting the Kukbo judgment, as well as the performance of the Talicia collaboration. The geopolitical risks in Israel also add a layer of uncertainty.

Keywords

Biopharma, SEC F-1, Equity Line, ADSs, Dilution, Nasdaq Compliance, Talicia, H. pylori, Cumberland Pharmaceuticals, YA II PN, Standby Equity Purchase Agreement, Kukbo Litigation, Israel, Pharmaceuticals, Clinical-stage, Commercialization, Financing